Brind.

AbbVie's CEO, Robert A. Michael, is linked to pre-IPO investments, with Benzinga reporting financial data and Kevin O'Leary commenting on strategies.

1 report, 1 independent Updated Aug 26

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

AbbVie Benzinga Kevin O'Leary

Keep exploring

The entities involved

AbbVie
pharmaceutical company
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
Benzinga
American news channel
- Benzinga reported on the recent stock price activity of SpaceX.Mon 02:14
- Benzinga reported analyst expectations for Jabil.Mon 02:08
Kevin O'Leary
Canadian businessman and television personality (born 1954)

Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped

Aug 26BenzingaHow To Put $100 In Your Retirement Fund Each Month With AbbVie Stock Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AbbVie Inc. (NYSE:ABBV) is a